Royal Bank of Canada
RPRX icon

Royal Bank of Canada’s Royalty Pharma RPRX Stock Holding History

Royal Bank of Canada’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Buy
185,821
+5,919
+3% +$308K ﹤0.01% 2036
2026
Q1 		$8.63M Buy
179,902
+23,479
+15% +$1.03M ﹤0.01% 2016
2025
Q4 		$6.05M Sell
156,423
-270,685
-63% -$10.3M ﹤0.01% 2279
2025
Q3 		$15.1M Buy
427,108
+120,130
+39% +$4.35M ﹤0.01% 1871
2025
Q2 		$11.1M Buy
306,978
+103,218
+51% +$3.42M ﹤0.01% 1968
2025
Q1 		$6.34M Buy
203,760
+160,191
+368% +$5.08M ﹤0.01% 2085
2024
Q4 		$1.11M Sell
43,569
-336,865
-89% -$8.93M ﹤0.01% 3455
2024
Q3 		$10.8M Sell
380,434
-27,652
-7% -$766K ﹤0.01% 1734
2024
Q2 		$10.8M Sell
408,086
-401,921
-50% -$11.1M ﹤0.01% 1629
2024
Q1 		$24.6M Buy
810,007
+316,439
+64% +$9.33M 0.01% 1148
2023
Q4 		$13.9M Buy
493,568
+79,291
+19% +$2.18M ﹤0.01% 1504
2023
Q3 		$11.2M Sell
414,277
-99,621
-19% -$2.96M ﹤0.01% 1497
2023
Q2 		$15.8M Buy
513,898
+142,349
+38% +$4.82M ﹤0.01% 1294
2023
Q1 		$13.4M Buy
371,549
+4,433
+1% +$164K ﹤0.01% 1373
2022
Q4 		$14.5M Sell
367,116
-3,017
-0.8% -$126K ﹤0.01% 1360
2022
Q3 		$14.9M Buy
370,133
+1,641
+0.4% +$70.1K ﹤0.01% 1261
2022
Q2 		$15.5M Sell
368,492
-123,650
-25% -$5.07M ﹤0.01% 1271
2022
Q1 		$19.2M Buy
492,142
+45,430
+10% +$1.78M ﹤0.01% 1260
2021
Q4 		$17.8M Buy
446,712
+23,450
+6% +$911K ﹤0.01% 1461
2021
Q3 		$15.3M Buy
423,262
+68,527
+19% +$2.66M ﹤0.01% 1527
2021
Q2 		$14.5M Buy
354,735
+221,771
+167% +$9.43M ﹤0.01% 1565
2021
Q1 		$5.8M Buy
132,964
+121,406
+1,050% +$5.76M ﹤0.01% 2127
2020
Q4 		$579K Buy
11,558
+4,846
+72% +$206K ﹤0.01% 4015
2020
Q3 		$284K Buy
6,712
+3,225
+92% +$138K ﹤0.01% 4297
2020
Q2 		$170K Buy
+3,487
New +$173K ﹤0.01% 4552

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada's RPRX Position: Q2 2026 in Review

Royal Bank of Canada increased its Royalty Pharma (RPRX) stake by 3.3% in Q2 2026, buying an estimated $308K and bringing the position to 185,821 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2036.

Royal Bank of Canada first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. The position peaked at $24.6M in Q1 2024. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Royal Bank of Canada held 185,821 shares of Royalty Pharma worth $10.4M as of Q2 2026.
  • Royal Bank of Canada bought 5,919 Royalty Pharma shares in Q2 2026, an estimated $308K.
  • Royalty Pharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #2036 holding.
  • Royal Bank of Canada first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • Royal Bank of Canada's Royalty Pharma position peaked at $24.6M in Q1 2024.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.